We aim to foster a culture of entrepreneurship, innovation and success among engineers in the UK, creating economic growth and societal impact. At the heart of how we do this are the Hub Members, the promising entrepreneurs who we support through our programmes, and our Hub Mentors, the business leaders who volunteer their expertise and time to help the Hub Members succeed.
From manufacturing to medtech, our Hub Membership is made up of some of the UK’s most innovative entrepreneurs. But don’t just take our word for it: read more about our Hub Members to see how they are, without exaggeration, changing the world.
Gallium nitride (GaN) has been dubbed the silicon of the future. It has properties that can give it an edge in the market including better energy efficiency, higher power and frequency operation than any other semiconductor material.
However, to make GaN widely available and get it adopted by the semiconductor industry (which is built almost entirely on silicon), there has to be a lower manufacturing cost and improved product performance.
Dr Tongtong Zhu is as a member of the Cambridge Centre for Gallium Nitride, and a co-founder of Porotech. The company, a University of Cambridge spin-out, has developed a new production process to make ‘porous GaN’. Porous GaN is a composite of solid GaN semiconductor and air. The company can create GaN with nanoscopic holes in it, from which it can engineer a wide range of material properties such as optical, mechanical, thermal and electrical. Essentially, it is offering a brand new material platform for semiconductor devices to be built upon.
In April 2020, Porotech closed a £1.5 million seed round investment that will allow it to develop a pilot plant in Cambridge, from which to launch its first products, enable customer validation and evaluation. Its first targeted market is LEDs. The company will supply highly reflective GaN mirror wafers to the epiwafer market - the essential base material to make LED chips - which will reach $2.3 billion by 2021.
Its second market focus will be for high power GaN devices. The company will sell porous strain compliance technology and GaN-on-silicon wafers for the emerging GaN power device market.
Dr Zhu says: “The pilot plant will start with small-scale production to show that our wafers can be made in volume and then potentially produce thousands a year.” Eventually, Porotech could license out its technology.
Dr Zhu joined the SME Leaders programme in September 2020 with ambitious plans to scale up his business. He wants to let go of some of the technical development responsibilities at the company and take on more of the business and management duties. Tongtong feels that the mentoring scheme and entrepreneurial courses will give him the leadership skills needed to take Porotech into its next phase of growth.
Porotech will start raising Series A investment in 2021, which will enable the company to start manufacturing its own semiconductor devices and products and licensing to address the worldwide market opportunity.
2018 – Porotech won Cambridge Enterprise’s Postdoc Business Plan Competition 2018
2019 – Porotech won the
gold award of the fifth China “Internet Plus” Innovation and Entrepreneurship
2019 - Dr Tongtong Zhu was awarded an Enterprise Fellowship
2020 – Closed a £1.5 million seed round investment
Visit their website: www.porotech.co.uk
In a global analysis of all the plastic ever made, the peer-reviewed journal Science Advances estimated that of the 8.3 billion tonnes that has been produced, 6.3 billion tonnes has become plastic waste. With only 9% recycled, the vast majority is accumulating in landfills or in the natural environment as litter. If present trends continue, by 2050, there will be 12 billion tonnes of plastic in landfills.
Many feel that a circular economy that considers the end destination of what is manufactured would help manage material production responsibly. From buttons to car doors, and spectacles to countertops, the use of sustainable alternatives to petroleum plastics would offer multiple plastic end-of-life scenarios.
Rowan Minkley, is the Co-Founder and CEO of Chip[s] Board. Chip[s] Board is a bioplastic technology company that converts food waste into bioplastics. It currently produces polymers and composites. The composites are natural-fibre reinforced melt blends for applications such as furniture, fashion and consumer electronics.
The company has developed a process to convert waste food by-products into a trademarked bioplastic called Parblex®. The main ingredient for this is upcycled potato scraps, supplied by the global food processing giant McCain Foods. By combining this with natural fibres, biobased composites can be made that are biodegradable and recyclable at the end of their product life. Parblex® is compatible with injection moulding, 3D printing, milling and other industrial processing techniques.
Rowan says: “Many current bioplastics are produced from virgin food crops – such as corn or sugar beet – that are grown specifically to create the materials needed for creating the bioplastic substance. Our philosophy is that a circular economy within waste (by-product) management and material production will create a new sustainable model, utilising the abundant resources we already have rather than continuing to process virgin materials.”
Chip[s] Board’s team is currently looking into the waste stream to find new materials to upcycle and diversify their product lineup.
2017 - Company founded
2018 - Shell LiveWIRE Award, Creative Conscience Award, Santander Entrepreneur of the Year
2018 - Rowan Minkley was awarded an Enterprise Fellowship
2018 - Rowan won the Launchpad Competition
2018 - McCain secured as a material supplier
2018 - Raised pre-seed Angel investment
2018 - Team expands to five full time staff
2019 - Relocation to Leyton warehouse, 100-litre production line established
2019 - Received Business of Fashion, Textiles and Technology SME grant and Knowledge Transfer Network Spark Award
2020 - Team expands to seven full time staff
Visit their website: www.chipsboard.com
In order to detect potential machine failure, oil samples are taken from heavy machinery such as compressors, gear boxes, generators or engines, then analysed by laboratories. By analysing oil samples, owners and operators can tell how well the machinery is performing and when the machinery will break down. Undetected and unsolved lubrication degradation and contamination can lead to early failure of key components, with significant cost implications.
There is a large financial expense associated with sampling, and a risk that the machinery could breakdown before the sample results come back from the laboratory.
RAB-Microfluidics has developed microfluidic ‘lab-on-a-chip technology’ to enable real-time continuous testing and analysis of lubricating oil. Microfluidic technology allows the manipulation of small volumes of fluids to control chemical, biological, and physical processes that can be used for sensing.
The company combines hardware technology with machine-learning that analyses the big data generated from its hardware. This offers customers real-time continuous monitoring, early problem diagnosis, rapid decision-making, enhanced efficiency and cost savings.
Surakat Kudehinbu, Product Engineer of [PS1] RAB-Microfluidics, says: “We will transition businesses from reactive to predictive maintenance strategies with data from our hardware device and our predictive maintenance service.”
The company is focused on commercialising the technology, with paid pilot trials helping develop an understanding of the commercialisation requirements of the technology in target markets, with a specific focus on the maritime and wind sectors.
RAB-Microfluidics estimate that its technology can reduce maintenance costs by 25% to 30% and can lead to a reduction in downtime caused by break downs and maintenance by 35% to 45%. It is aiming for its first sale in the first quarter of 2021.
Surakat says that the Enterprise Fellowship programme has helped the company in a number of ways: “It’s given us access to high-level insightful industrial knowledge, has helped up develop appropriate business models for our market segments, and brought us closer to commercialisation.”
2017 – Energy Technology Partnership grant
2017 – Oil and Gas Innovation Centre Grant
2017 – UKRI Innovate UK Grants (Materials and Manufacturing – Round 3 )
2017 – UKRI Innovate UK Grants (Infrastructure systems - Round 3)
2018 – OGTC Tech X –BP technology prize
2018 – Scottish Edge award
2018 – Scottish Enterprise High Growth Ventures Programme
2019 – Surakat Kudehinbu was awarded an Enterprise Fellowship (1851 Royal Commission)
Visit their website: www.rab-microfluidics.co.uk
The analysis of proteins and small molecules for drug research and manufacturing involves slow and expensive testing. New processes that could speed up and enable high-sensitivity testing are needed.
Dr Ruizhi Wang’s expertise lies in the large-scale manufacturing of 2D materials – aka single-layer materials. He is a co-founder of The Hofmann Group spin out, HexagonFab. The company is using 2D crystalline materials to develop biosensors for medical applications.
The first sensor it has produced, called HelloProtein, will give drug development researchers the ability to characterise proteins and understand biomolecular interactions through a handheld device. The company says it is both faster and more reasonably priced than rivals operating in the same field.
Before HexagonFab, low-cost and large-scale
manufacturing of high-quality graphene was not possible. Only small amounts –
enough for research – were being made. The company’s ability to fabricate at
commercial-scale using chemical vapour deposition, along with related
atomically-thin materials, means that it can focus on generating very sensitive
and fast sensors.
HelloProtein is a field-effect transistor (FET) biosensor driven by graphene. Changes in the electrical charges in its environment affect the electrical properties of the graphene layer. This enables it to detect minute electrical charge changes allowing the detection of biomolecule-binding with high precision.
Dr Wang believes that such bioFET sensors could have a variety of other applications in the fields of medical diagnostics and industrial monitoring. The global market for drug development equipment is huge and by mid-2020 the company had already made £35,000 of sales.
2018 HexagonFab founded
2018 Merck’s Displaying Futures Award ($50,000 financial backing plus collaboration)
2018 Winner of Materials and Enabling Technologies category of Royal Society of Chemistry’s Emerging Technologies
2019 InnovateUK grant
2020 AMS corporate challenge winner
2020 First product sales
Visit their website: www.hexagonfab.com
Time is of the essence when providing emergency medical support. Metix Medical has developed Coremed, a light, portable monitoring device that rapidly gathers a patient’s vital medical information, enabling first responders to quickly make decisions about treatment and the right place for care.
The Coremed device constantly monitors a person’s medical data and stores it both locally and in a remote monitoring platform in real time. This information can be exported automatically or on demand for further clinical review or record keeping. Metix Medical's platform can keep track of multiple patients simultaneously, ranking them based on severity with its heavily-automated patient scoring engines.
The company has raised
over £ 4 million in grants and funding since inception, which has enabled it to
continue developing its triaging technology. It is now looking to gain market
entry in North America and establish market clearance for its products
Julio says that the SME Leaders programme has “provided training that helped me to plan the right course of action both for our R&D activities and commercial decision-making. The regular roundtables with other SME Leaders also provide a safe space to discuss a variety of business issues.”
Dr James Gough is a former military and humanitarian aid doctor who has worked with the British Army and the International Committee of the Red Cross. In 2018, James set up One Shot Immersive to create virtual reality medical and situational awareness training to help save lives.
This new startup launched its first beta product in Yemen in January 2020. Funded by a Danish foundation, its 360° virtual reality (VR) experience is an interactive mass-casualty triage training tool for doctors and healthcare workers. The VR gives them an immersive experience of a traumatic conflict situation, enabling them to recognise injuries that vary in severity. It also shows how to clinically prioritise and treat them.
The vision for One Shot Immersive is to deliver virtual reality that empowers people to save lives. The company intends to become a leader in supplying virtual reality medical training to conflict zones and the world’s most remote and hard-to-access regions.
James says that the SME Leaders programme “gave me the confidence to share ideas and challenge my own, and other people’s assumptions, about them. It also played a key part in my transition from being an employee to starting my own company.”
Q-Bot Ltd uses robotics, 3D scanning, digital tools and AI to help contractors inspect, maintain and upgrade buildings. Uninsulated floor in a typical suspended timber floor home can be responsible for 20% of heat loss. Q-Bot’s patented small robots are placed under the floorboards, where they spray insulation on the underside of the boards to stop draughts and heat loss through the floor.
The result is a significant reduction in energy use and CO2 emissions. In 2020 the company’s work was recognised with a Queen’s Award for Enterprise in the Innovation category. Q-Bot now offers a range of solutions that can identify the needs of individual properties, automate repetitive tasks, reach inaccessible areas and track the work done.
Mathew Holloway is Co-Founder and CEO of Q-Bot. He leads the company’s overall strategy, fundraising and team. He says that he benefitted from the SME leaders programme through the practical lessons it gives to solve real business challenges and the opportunities it gave him for personal development.
Q-Bot has a busy few years coming up. In 2019 it received financial backing from several investors, including the French multinational Saint-Gobain. The £3.6 million initiative will enable Q-Bot to extend its operations from the UK into France and the Netherlands.
It is estimated that a third of the food grown worldwide, around 1.3 billion tonnes, is not eaten and goes to waste at a cost approaching £1 trillion. In the UK, the cost of food waste from households totals £9.7 billion, while in the hospitality and food sector businesses alone it has been evaluated at £2.5 billion.
To avoid the negative impacts from food waste including huge greenhouse gas emissions and lack of sufficient landfill spaces, London is aiming to be a zero-waste city by 2026 with no biodegradable or recyclable waste sent to landfill. Scotland has a target to ban food waste to landfill or sewer by January 2021. Overall, the UK’s target date is 2030. With existing solutions, these targets cannot be met.
Ifeyinwa Kanu is the founder and director of IntelliDigest Ltd, a start-up company from Heriot-Watt University. At IntelliDigest, Ifeyinwa is combining biotech and deep-tech software to develop a user-friendly, odour-free and patented ID Box and IntelliTrade platform that can be used at home, in the work place and within the hospitality sector to convert food waste to climate friendly chemicals.
Using the ID Box can eliminate exposure to long-term health problems such as asthma and chronic obstructive pulmonary disease. These can arise from the bioaerosols from microorganisms growing quickly and degrading food waste during collection, handling and composteing.
The ID Box uses artificial intelligence and embedded sensors to characterise food waste, then optimises the enzyme dosing that breaks it down producing bio-chemicals. The biochemicals are analysed using embedded sensors and the information is then made available on IntelliDigest’s blockchain trading platform, where it can be purchased by registered businesses and converted into biodegradable packaging or 3D printed items.
Ifeyinwa says: “My vision for IntelliDigest is to be the go-to-market solution that enables a more environmentally-friendly and holistic way of dealing with food waste at home, work and hospitality outlets. Our technology will help repurpose inedible food waste by creating high value climate-friendly chemicals, thereby boosting the bio-economy without adverse impact on the environment.”
Marriott Hotels, Radisson Hotels and the InterContinental Hotels Group have signed up for paid trials of IntelliDigest’s ID Box technology and the company is now looking to secure £500,000 investment by the end of 2020 to complete manufacturing and commence commercialisation.
2016 – Created
2017 – Winner of the Institution of Engineering and Technology Innovation Award
2018 – Established a partnership with Bosch for subcontracted commercial manufacture of ID Box
2019 – Joined Telefonica/Wayra AI & Blockchain Accelerator
2019 – Awarded an Enterprise Fellowship
2019 – Company signs trial contracts in the UK with Marriott Hotels and Radisson Hotels
2019 – Accepted on the Novozymes' HelloScience innovation hub
2020 – Accepted on Mayor of London’s Better Futures programme
Visit their website: www.intellidigest.com
External medical devices that attach and apply pressure to the skin, such as prosthetics, orthotics and respiratory masks, often do not fit properly, leading to pain and injury for the user. An average of nine clinical visits is usually required before a comfortable fit is achieved for a prosthetic limb after amputation. The lack of analytical tools can result in the fitting of these bespoke devices becoming a lengthy and frustrating process.
Radii Devices aims to improve the fit of external medical devices and increase the quality of life for patients. Dr Joshua Steer formed the company as a spin-out from the University of Southampton’s Bioengineering Sciences Research Group in 2019. It exploits the biomechanical modelling and analysis he has developed to give clinicians more accurate predictions of fit during the prosthetic socket design process.
Imaging techniques, such as laser and MRI scanning are used to capture the shape of the individual’s limb. This enables Radii Devices to track shape change over time, generate computational models to predict pressure at the limb-prosthetic interface, and compare results across the population to forecast the comfort of a particular socket. Healthcare professionals can then view this analysis to support their choice of optimal socket.
The World Health Organization estimates that 30 million people worldwide are in need of prosthetic and orthotic devices. This number is due to rise, driven by an ageing population and increasing incidence of diabetes, which is the leading cause of amputation.
As an engineer, Joshua wants to solve real-world problems. His technology could be applied to any external medical device that applies pressure to the skin such as ankle-foot orthoses, wheelchair seating, and footwear. The company is running clinical pilots of its software in 2020 aiming to achieve full product launch soon after. Radii Devices is simultaneously working on collaborative projects for other medical devices such as respiratory face masks for intensive care, to help manufacturers improve the quality of fit.
Joshua says: “The Fellowship has given Radii Devices the best possible launchpad to translate our research into clinical and commercial use. It has provided us with the skills, expertise and support to refine our business model, raise our first funding round and commence clinical pilot studies.”
2015 Institute for Mechanical Engineering (iMechE) Vicon
2019 Dr Joshua Steer was awarded an Enterprise Fellowship
2019 Radii Devices spun out of the Bioengineering Sciences Research Group at University of Southampton
2019 Secures £100,000 of investment at Future Worlds Dragons’ Den event
2020 Launched at the Consumer Electronics Show
2020 Commences pilot studies of the software with clinicians
Visit their website: www.radiidevices.com
What makes us different is the Academy’s Fellows and our wider Mentor network – an unrivalled community of the UK’s most successful industry leaders, technology experts and entrepreneurs. Find out more about our Mentors and their areas of expertise.
Dr Supti Sarkar leads the Technology and Investments Group at PwC. She is responsible for the commercialisation of new tech ventures across the firm, and works with in-house entrepreneurs to get their products market ready.
Supti was formally a management consultant at PA Consulting, where she worked with international and regional governments to support their trade and investment strategies. She was also part of Mayor Sadiq Khan's 2016 delegation to Chicago and New York as part of her role in supporting high growth companies entering the US market for the first time. Supti holds a first class degree and PhD in engineering from University College London and is mum to an eight-year-old daughter.
Dr Douglas C Anderson OBE FREng FRSE has a 40-year business career covering almost every aspect, at every level, of healthcare technology product design and product commercialisation processes.
Having trained in industrial design engineering (Edinburgh Napier University 1974), Douglas progressed from hands on designer to the management of design in the high-tech arena.
Using his consulting company Crombie Anderson as a base for innovation and incubation, he subsequently spun out three other high-tech startup companies, two of which became publicly traded business operating in medical fields.
Douglas was the prime mover in these businesses by leading both the innovation and commercialisation processes, including raising over £40 million in private and institutional funding prior to floatation. Today he is internationally recognised for his innovation and entrepreneurial experience and is a regular keynote speaker at healthcare and business congresses around the world.
In 1990, his five-year-old son Leif suffered a spontaneous retinal detachment that went undetected until it was too late to treat. Douglas was struck by the limited capability of diagnostic tools available to practitioners to examine the retina and decided to address this issue. He built a dedicated research team, which led to the formation of Optos plc, a business funded by Archangel from the outset.
Optos succeeded in designing and patenting a scanning laser ophthalmoscope: the world's first ophthalmic device that enabled eye care professionals to capture a digital ultra wide-field image of the almost the entire retina in a single scan. The new method of examining the retina, marketed as the optomap® Retinal Exam, is now offered as the preferred standard of care by tens of thousands of eye-care specialists globally. Over 200 million optomap® retinal exams have been conducted worldwide and a number of novel diagnostic techniques added to improve the understanding and treatment of a wider range of conditions that have been historically difficult to manage.
In 2006 Douglas was awarded an OBE for services to healthcare. Douglas was elected a Fellow of the Royal Academy of Engineering in 2013.
David is an investor and CEO with companies based on technology and innovation.
After a degree in electrical engineering at the Technion and an MBA from INSEAD, David worked his way to senior management and board level in a wide range of sectors including sustainability, construction, life sciences, manufacturing, mobile telephony, cyber security and software. His broad experience ranges from startups to public companies, from turnaround missions and crisis management to business development and growth.
David is deeply involved in the UK startup space, as a member of UKBAA, VCs, EIS funds and university angel groups, and is an active mentor with the Royal Academy of Engineering and Imperial College London’s IVMS programme. He also serves as a non-executive on the board of directors of Kerur Holdings (a public company), the board of governors of the Technion, as an advisor with the US accelerator Silicon Catalyst and the board of trustees of Hadassah UK.
He believes that success comes from a culture of excellence, a multidisciplinary approach, and that the boundaries between B2B/B2C and startups/LargeCo are increasingly blurred.
"Startups challenge and can defeat established companies. An explosion of new technologies will accelerate this trend. Large companies cannot afford to be on the defensive, they must proactively adopt a startup culture. But startups must also learn to be humble and pragmatic, build structures, communicate at a senior level, and strive to serve all their stakeholders, clients, staff, investors, and society as a whole. A fusion of cultures is now pivotal to success."
Richard joined sustainability investment focused Earth Capital Group in 2009 and has worked both on the group’s investment in investment managers and direct growth company investments, including most recently the fund’s investments in SoftIron and Propelair. He takes a leading role in promoting technology transfer opportunities across the group’s international offices.
Prior to joining Earth Capital, Richard was an Investment Director with IBIS Asset Management Ltd, a London-based captive advisor to a large Caribbean conglomerate. Richard was earlier a senior manager in the London office of L.E.K. Consulting, a global strategy consultancy. During his five years with LEK he provided due diligence advice, in numerous large cap and mid-market private equity deals, and advised corporate clients on corporate strategy, business unit growth strategy, process redesign and cost reduction programmes.
A chartered engineer, his early career included successful engineering, operations and customer support management roles with Ford Motor Company and Visteon Corporation. Richard holds an MBA with Distinction from INSEAD and MEng and MA (First Class) degrees in engineering from the University of Cambridge. He is a chartered member of the Chartered Institute of Securities and Investment, and a Chartered Member of the Institute of Engineering and Technology and a Sainsbury Management Fellow.
Dr Andrew Hosty FREng is an international leader with over 15 years of non-executive board experience and 30 years of executive and management experience, spanning private equity, UK Plc and global blue-chip corporates. He is non-executive director of a companies including: RHI-Magnesita, the global leader in the manufacture and supply of refractories; James Cropper Plc, who create some of the world’s most distinctive and technically advanced paper products; and Rights and Issues Investment Trust Plc, a fund that focuses on small cap UK industrials.
Andrew is Non-Executive Chairman of mOm Incubators ltd, a pre-revenue startup developing low-cost baby incubators for crisis zones. He is also Non-Executive Chairman of Nexeon ltd, a company developing next-generation cathode materials for lithium-ion batteries. From 2016 to 2018 Andrew was the CEO of the Sir Henry Royce Institute, the UK's home of advanced materials research and innovation. He was Chief Operating Officer of Morgan Advanced Materials, and served on the Plc Board as an Executive Director from 2010 to 2016.
From 2013 to 2016 he served on the board
of Consort Medical Plc, a healthcare company focused on developing advanced
delivery technologies, formulation and manufacturing solutions for drugs. He is
a Fellow of the Institute of Materials, holds a PhD from the Faculty of
Engineering at the University of Sheffield and is a Fellow of the Royal Academy
of Engineering (2011).
Chris McIntosh joined Methera Global as CEO in 2017. The company’s vision is to enable the delivery of digital applications to rural and underserved communities worldwide via a resilient constellation of Ka band MEO satellites. He previously spent seven years as CEO of ViaSat UK where he was responsible for the inception and growth of ViaSat’s UK satellite capabilities. Headquartered in the US, ViaSat are renowned as being one of the most disruptive players in the satellite communications and security domain.
Before joining ViaSat Chris was CEO of Stonewood Group, developers of state-of-the-art cyber products and services. He is a retired Lieutenant Colonel from the British Army and has worked within the challenging, high threat cyber and communications environment for over 30 years. He holds a BSc in computer science, MSc in design of computer systems and an MBA. He is a member of the UKspace trade association and the National Security and Resilience Consortium, and is a chartered engineer.
Roy Williamson has been helping companies see how their new innovations can disrupt markets for over 20 years.
For the past six years has been successfully helping early stage companies identify and define their strengths, enhance their uniqueness and develop their storylines to engage investors. Roy’s background is in engineering and cleantech and since 2013, he’s been supporting SMEs and entrepreneurs across a broad area of technologies and innovative business models.
Roy is an aeronautical engineer and started his career at Alstom, developing algorithms and models to estimate hardware costs of power generation gas turbines based purely on, often novel, thermodynamic cycles. He has assessed innovation ecosystems of the UK, published by the Organisation for Economic Co-operation and Development. He has also co-authored guides to support technology developers in the UK automotive sector assess technology readiness levels and help those in the biofuels sector to review pathways for second generation biofuels. He’s appraised novel technology solutions for blue-chip clients, developed proof of concepts and carried out due diligence activities to support investor decision making. He is passionate about the UK and knowledge-intensive companies, from software to deeptech.
Roy is Head of Origination at the Department for International Trade with relationships across the department’s teams, government and the UK’s innovation and investment ecosystem.
Professor Mark Arthur Tooley FREng is the immediate Past President of the Institute of Physics and Engineering in Medicine. He was the Head of the Department of Medical Physics and Bioengineering and Director of Research and Development at the Royal United Hospitals, Bath until 2017 when he retired from full-time NHS work. Since then, he has held several part-time roles. He is a specialist scientific advisor for NHS England, a digital clinical advisor for the West of England Academic Health Science network, and a healthcare technology consultant. He is a registered Consultant Clinical Scientist, an honorary professor at the University of Bath, and a visiting professor at the University of the West of England.
Mark completed his BSc in Electrical and Electronic Engineering at the University of Bath in 1979. He was sponsored by Westinghouse Brake and Signal company for the four years of the course. He then did an MSc and PhD in Medical Physics at the University of London. His MSc thesis was developing a EEG frequency analyser for anaesthesia. For his PhD research, Mark invented (with a cardiologist) an original method for rate-independent diagnosis of cardiac rhythm for implantable devices, which was patented. He spent the rest of his career in Medical Physics and Bioengineering departments, both in hospitals and academia, working along medical colleagues. He has worked at St Bartholomew’s hospital in London, Bristol University, United Bristol healthcare NHS Trust, and the Royal United Hospital, Bath. He is a Fellow of the Royal Academy of Engineering, the Royal College of Physicians, the Institute of Engineering and Technology, the Institute of Physics and Engineering in Medicine, and the Institute of Physics. He is a chartered engineer and chartered scientist. Mark is on the peer-review college of EPSRC, has recently been a member of the Engineering and Physical Sciences Research Council Healthcare Technologies Strategic Advisory Team and the Royal Society Fellowship panel.
Mark has been a long-standing member of the Panel for Biomedical Engineering at the Royal Academy of Engineering (now called the healthcare policy topic group). He was recently a member of the biomedical engineering membership panel, the Policy Committee, and the working group for Systems thinking in healthcare. He has mentored on the enterprise scheme.
Mark’s research interests include innovations in medicine, physics applications in anaesthesia, simulation in medicine, physiological measurement, biological signal processing, measuring the depth of anaesthesia, blood pressure measurement and novel patient monitoring solutions.
Dr Liane Smith FREng founded Intetech Ltd in 1991, winning the Queen’s Award for Innovation in 2012 for its software. She sold the business to Wood Group in 2013 and in 2018 she left to form a new consulting engineering business, Larkton Ltd.
Liane is enthusiastic about the capability of digital technologies to transform businesses, bringing efficiencies, cost reduction, production control and increasing safety. In her last role as Senior Vice President Digital Solutions for Wood, she built the new global service line and defined its strategy roadmap and development plan. Her expertise is in various specialist branches of engineering in the industrial and energy sectors and in software product design and commercialisation, data management, data analysis, and analytics.
“I try to fill in gaps in mentees experience and give them confidence in their decisions. Typically we touch on building strong teams, role and task delegation, agile development, growing sales, exporting and strategy."